Efficacy, Safety, and Predictors of Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: Results of a Multicenter Prospective Clinical Series

What Was Tested

This clinical trial paper looks at Methylene blue (non-peptide stack partner).

A substantial part of chronic LBP is attributable to degenerative changes in the intervertebral disc.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Prospective clinical study of intradiscal methylene blue injection for the treatment of lumbar discogenic pain.

Patients were selected on clinical criteria, magnetic resonance imaging, and a positive provocative discogram.

How the Study Was Run

The design is described as randomized, double-blind and pilot.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

It is described as a pilot, a small early test of whether a larger Methylene blue (non-peptide stack partner) study would be practical.

What Was Measured

PubMed files the paper under topics including Intervertebral Disc, Intervertebral Disc Displacement, Low Back Pain, Methylene Blue, Netherlands, Pilot Projects and Quality of Life.

Author keywords: chronic pain and refractory pain.

What This Means in Plain Language

The paper is a randomized, double-blind and pilot study of Methylene blue (non-peptide stack partner).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Pain practice : the official journal of World Institute of Pain), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.